Lifeway Foods Commends New Research Further Positioning Kefir as a Potential Protective Dietary Supplementation Against Bacte...
April 15 2021 - 12:43PM
Lifeway Foods, Inc. (Nasdaq: LWAY) (“Lifeway” or “the Company”),
the leading U.S. manufacturer of kefir and fermented probiotic
products, applauds the recent study published in Microbiome which
identified molecules in kefir that proved to be effective at
treating various inflammatory conditions, including “cytokine
storms” caused by COVID-19 and other diseases that attack the
immune system.
This study serves as the most recent extension of previous
research that highlights how kefir and its anti-inflammatory &
anti-microbial properties may help inhibit the growth of pathogens
and reduce inflammation for appropriate immune response, and as a
result help maintain the gut microbiome to support a healthy immune
system. Key findings from the study include the following:
- This study reports interference with quorum sensing pathways in
human pathogens induced by a probiotic yeast- K. marxianus. We
identified a specific compound—tryptophol-acetate—secreted
by K. marxianus, which disrupted CAI-1 QS cascades
in V. cholerae, significantly modified V.
cholerae biofilm formation and morphology, and reduced
bacterial virulence. [1]
- These results are notable, since this is the first
demonstration that QS in human pathogenic bacteria can be modulated
by molecules secreted by probiotic yeast. [1]
- Findings suggest that distinct symbioses in multi-microorganism
populations may be maintained by secreted QS-modulating molecules.
Such cross-kingdom QS interfering molecules may play important
roles both in fermented milk products, in the digestive system of a
person consuming the mixtures, and possibly also in the gut
microbiome in general. [1]
- These potentially universal effects may account for
pathogen-combating properties of the human microbiome and could aid
elucidating health benefits of probiotic microorganism products.
[1]
While COVID-19 vaccines are becoming increasingly accessible
across the globe, Lifeway hopes that this new research further
equips consumers with information to keep themselves and their
families as safe and healthy as possible throughout the
pandemic.
“At Lifeway Foods, we are proud to applaud and amplify
innovative research that has the potential to keep our communities
healthy, and we’re especially grateful for such timely research
when immunity is at forefront of conversation,” states Julie
Smolyansky, CEO of Lifeway Foods, Inc. “The recent COVID-19
pandemic may eventually lead to a deeper understanding of how
wellbeing is affected by probiotics and digestive health, and once
again we’re seeing studies that build upon the foundation of Nobel
Prize winner Élie Metchnikoff’s research on immunology. We will
continue to honor his legacy by celebrating the ongoing research
and spreading the word about the benefits of probiotics and
kefir.”
As the leading U.S. supplier of kefir, Lifeway Kefir is made
with 12 active cultures and packed with protein, calcium and
vitamin D. Each product is loaded with probiotics, which research
suggests may help to support the microbiome and protect against
infections. Additionally, research suggests that probiotic products
such as Lifeway Kefir may help support the body’s response to
decrease inflammation.
To learn more about Lifeway and its products,
visit lifewayfoods.com. To view the full study published in
Microbiome Volume 9, visit Biomedcentral.com
About Lifeway
Foods
Lifeway Foods, Inc., which has been recognized as one of Forbes’
Best Small Companies, is America’s leading supplier of the
probiotic, fermented beverage known as kefir. In addition to its
line of drinkable kefir, the company also produces cupped kefir and
cheese, frozen kefir, specialty cheeses, probiotic supplements and
a ProBugs line for kids. Lifeway’s tart and tangy fermented dairy
and non-dairy products are now sold across the United States,
Mexico, Ireland and the United Kingdom. Learn how Lifeway is good
for more than just you at www.lifewaykefir.com
Forward-Looking
Statements
All statements in this release (and oral statements made
regarding the subjects of this release) contains “forward-looking
statements” as defined in the Private Securities Litigation Reform
Act of 1995 regarding, among other things, future operating and
financial performance, product development, market position,
business strategy and objectives. These statements use words, and
variations of words, such as “expect,” “vision,” “will,” “predict,”
“grow,” and “trend.” Other examples of forward looking statements
may include, but are not limited to, (i) statements of Company
plans and objectives, including the introduction of new products,
or estimates or predictions of actions by customers or suppliers,
(ii) statements of future economic performance, and (III)
statements of assumptions underlying other statements and
statements about Lifeway or its business. You are cautioned not to
rely on these forward-looking statements. These statements are
based on current expectations of future events and thus are
inherently subject to uncertainty. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from Lifeway’s expectations
and projections. These risks, uncertainties, and other factors
include: price competition; the decisions of customers or
consumers; the actions of competitors; changes in the pricing of
commodities; the effects of government regulation; possible delays
in the introduction of new products; and customer acceptance of
products and services. A further list and description of these
risks, uncertainties, and other factors can be found in Lifeway’s
Annual Report on Form 10-K for the fiscal year ended December 31,
2020, and the Company’s subsequent filings with the SEC. Copies of
these filings are available online at https://www.sec.gov,
http://lifewaykefir.com/investor-relations/, or on request from
Lifeway. Information in this release is as of the dates and time
periods indicated herein, and Lifeway does not undertake to update
any of the information contained in these materials, except as
required by law. Accordingly, YOU SHOULD NOT RELY ON THE ACCURACY
OF ANY OF THE STATEMENTS OR OTHER INFORMATION CONTAINED IN ANY
ARCHIVED PRESS RELEASE.
References:
[1] Malka, O., Kalson, D., Yaniv, K. et
al. Cross-kingdom inhibition of bacterial virulence and
communication by probiotic yeast
metabolites. Microbiome 9, 70
(2021). https://doi.org/10.1186/s40168-021-01027-8
Contact:
Lifeway Foods, Inc.Phone: 847-967-1010Email:
info@lifeway.net
Lifeway Foods (NASDAQ:LWAY)
Historical Stock Chart
From May 2024 to Jun 2024
Lifeway Foods (NASDAQ:LWAY)
Historical Stock Chart
From Jun 2023 to Jun 2024